MXCT
MaxcyteยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
MXCT Profile
Maxcyte, Inc.
A British biotech company pioneering cell therapies for refractory cancers, leveraging its proprietary CAR-T technology
9713 Key West Avenue, Suite 400, Rockville, Maryland 20850
--
MaxCyte, Inc., was incorporated on July 31, 1998 under the laws and regulations of the State of Delaware. The company is a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research and the discovery, development and commercialization of next-generation cell therapies. Over the past two decades, the company has developed and commercialized the proprietary Flow Electroporation platform, which facilitates complex engineering of various cells.
